news Stem cell study uncovers shared genes for hearing and vision repair 9 April 2025 | By Drug Target Review New research, led by USC Stem Cell scientists, has identified key genetic barriers to sensory cell regeneration in the ear and eye, paving the way for future drug therapies to restore hearing and vision.
news Identification of antibodies to target the NA globular head domain 5 March 2024 | By Drug Target Review The study's findings could be applied to the development of new vaccine and therapeutic strategies for influenza.
news $6 Million grant issued to Penn Medicine to investigate role of DNA in cardiac cell development 12 June 2023 | By Izzy Wood (Drug Target Review) Penn Medicine researchers are interested in how cardiac cells use DNA to establish and maintain their specification.
news Brain recordings could improve deep brain stimulation therapy for OCD 21 December 2021 | By Anna Begley (Drug Target Review) Scientists captured more than 1,000 hours of brain recordings from obsessive compulsive disorder (OCD) patients and uncovered candidate neurological signatures.
news New study may improve enzyme replacement therapy for Pompe patients 24 August 2021 | By Anna Begley (Drug Target Review) Researchers have developed a new method that could make enzyme replacement therapy more efficient for Pompe disease treatment.
article Open innovation – a collaboration between academia and the pharmaceutical industry to further leverage drug discovery expertise and assets 13 December 2019 | By Dr David Murray (AstraZeneca), Dr Mark Wigglesworth (AstraZeneca), Marian Preston (AstraZeneca) Increasing numbers of companies in the pharma industry are consolidating their services and outsourcing to CROs to reduce business costs. AstraZeneca’s Marian Preston, David Murray and Mark Wigglesworth discuss how this can not only drive innovation but also prove successful in identifying lead compounds, as evidenced through recent collaborations.
